Sign in →

Test Code MP1BC Microtubule-Associated Protein 1B (MAP1B) Antibody, Immunoblot, Spinal Fluid (Non-Orderable)


Specimen Required


Only orderable as a reflex. For more information see:

-DMC2 / Dementia, Autoimmune/Paraneoplastic Evaluation, Spinal Fluid

-ENC2 / Encephalopathy, Autoimmune/Paraneoplastic Evaluation, Spinal Fluid

-EPC2 / Epilepsy, Autoimmune/Paraneoplastic Evaluation, Spinal Fluid

-MAC1 / Myelopathy, Autoimmune/Paraneoplastic Evaluation, Spinal Fluid

-MDC2 / Movement Disorder, Autoimmune/Paraneoplastic Evaluation, Spinal Fluid


Useful For

Only orderable as a reflex. For more information see:

DMC2 / Dementia, Autoimmune/Paraneoplastic Evaluation, Spinal Fluid

ENC2 / Encephalopathy, Autoimmune/Paraneoplastic Evaluation, Spinal Fluid

EPC2 / Epilepsy, Autoimmune/Paraneoplastic Evaluation, Spinal Fluid

MAC1 / Myelopathy, Autoimmune/Paraneoplastic Evaluation, Spinal Fluid

MDC2 / Movement Disorder, Autoimmune/Paraneoplastic Evaluation, Spinal Fluid

 

Detecting paraneoplastic neurological autoimmunity using spinal fluid specimens

 

Identifying an underlying cancer

 

Better characterization of a patient’s neurologic presentation

 

Evaluating patients with paraneoplastic or autoimmune central nervous system inflammation (brainstem encephalitis or limbic encephalitis or cerebellar ataxia or myelitis) or peripheral nervous system inflammation (including polyradiculopathy or neuropathy) and using serum or cerebrospinal fluid specimens.

Method Name

Only orderable as a reflex. For more information see:

-DMC2 / Dementia, Autoimmune/Paraneoplastic Evaluation, Spinal Fluid

-ENC2 / Encephalopathy, Autoimmune/Paraneoplastic Evaluation, Spinal Fluid

-EPC2 / Epilepsy, Autoimmune/Paraneoplastic Evaluation, Spinal Fluid

-MAC1 / Myelopathy, Autoimmune/Paraneoplastic Evaluation, Spinal Fluid

-MDC2 / Movement Disorder, Autoimmune/Paraneoplastic Evaluation, Spinal Fluid

 

Immunoblot (IB)

Reporting Name

MAP1B Immunoblot, CSF

Specimen Type

CSF

Specimen Minimum Volume

1 mL

Specimen Stability Information

Specimen Type Temperature Time
CSF Refrigerated (preferred) 28 days
  Frozen  28 days
  Ambient  72 hours

Reference Values

Only orderable as a reflex. For more information see:

-DMC2 / Dementia, Autoimmune/Paraneoplastic Evaluation, Spinal Fluid

-ENC2 / Encephalopathy, Autoimmune/Paraneoplastic Evaluation, Spinal Fluid

-EPC2 / Epilepsy, Autoimmune/Paraneoplastic Evaluation, Spinal Fluid

-MAC1 / Myelopathy, Autoimmune/Paraneoplastic Evaluation, Spinal Fluid

-MDC2 / Movement Disorder, Autoimmune/Paraneoplastic Evaluation, Spinal Fluid

 

Negative

Interpretation

When positive, this test is strongly linked to small-cell lung carcinoma, occurring in approximately 80% to 90% of microtubule-associated protein 1B (MAP1B)-positive patients who have a malignancy. It also aids diagnosis across a broad clinical spectrum, including peripheral neuropathies such as painless subacute or chronic polyradiculoneuropathy and sensory neuronopathy, as well as central nervous system disorders like cerebellar ataxia, encephalopathy, myelopathy, and brainstem or cognitive dysfunction. Autonomic features and autoimmune gastrointestinal dysmotility may also occur. Together, these findings help healthcare professionals identify when an otherwise unexplained neurological syndrome may have a paraneoplastic cause.

Clinical Reference

1. Vernino S, Lennon VA. New Purkinje cell antibody (PCA-2): marker of lung cancer-related neurological autoimmunity. Ann Neurol. 2000;47(3):297-305

2. Gadoth A, Kryzer TJ, Fryer J, McKeon A, Lennon VA, Pittock SJ. Microtubule-associated protein 1B: Novel paraneoplastic biomarker. Ann Neurol. 2017;81(2):266-277. doi:10.1002/ana.24872

3. Jitprapaikulsan J, Klein CJ, Pittock SJ, et al. Phenotypic presentations of paraneoplastic neuropathies associated with MAP1B-IgG. J Neurol Neurosurg Psychiatry. 2020;91(3):328-330. doi:10.1136/jnnp-2019-322175

Day(s) Performed

Varies

Report Available

4 days

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.

CPT Code Information

84182

LOINC Code Information

Test ID Test Order Name Order LOINC Value
MP1BC MAP1B Immunoblot, CSF In Process

 

Result ID Test Result Name Result LOINC Value
621405 MAP1B Immunoblot, CSF In Process